Next Generation Proteomics Highlights

We are thrilled to join forces with Siemens Healthcare Laboratory to advance precision medicine. The agreement leverages Biognosys’ expertise in discovery proteomics for biomarker identification with Siemens Healthineers’ capabilities in biomarker assay development, clinical testing, and commercialization.

Biognosys has a strong presence at the 2021 AACR Annual Meeting with a minisymposium and three posters. The minisymposium highlights our work with AstraZeneca and ETH Zurich on Limited Proteolysis Mass Spectrometry (LiP-MS) for drug target identification. The posters showcase the results of various collaborations on drug target discovery and biomarker discovery.

Register now for our "Next-Generation Proteomics for Precision Oncology" webinar series with GenomeWeb, highlighting the impact of proteomics on clinical research in oncology and COVID-19. The first two webinars will take place on April 27 in collaboration with Jean-Marie Michot, MD, MS Sc from Gustave Roussy Institute and on June 16 in collaboration with Paolo A. Ascierto, MD from Istituto Nazionale Tumori Fondazione G. Pascale.

Proteomics has the potential to transform our understanding of biology and speed up drug development by reducing risks and increasing efficiency. Biognosys has perfected its Mass Spectrometry (MS) based proteomics technology so that thousands of proteins can be quantified across thousands of biological samples. Read more about how Large-Scale Discovery Proteomics can advance your research.

We have completely revamped our website to offer our customers and website visitors an appealing, user-friendly and engaging experience with our company, and continuously provide up-to-date and relevant information on our solutions. Check it out and let us know your feedback via this short survey.